CSIMarket
 

Healthcare Sector

In Vitro & In Vivo Diagnostic Substances Industry Growth  


Growth Rates by Company within In Vitro & In Vivo Diagnostic Substances Industry




Revenue Growth Net Income Growth
Company Quarter Y / Y Sequential Y / Y Sequential
Arca Biopharma Inc 3Q 2023 - - - -
Achieve Life Sciences Inc 3Q 2023 - - - -
Aspira Women s Health Inc 3Q 2023 up 7 % down -11 % - -
Biomerica Inc 2Q 2023 down-79.1 % down -0.29 % - -
Burzynski Research Institute Inc 4Q 2023 - - - -
Cardio Diagnostics Holdings Inc 3Q 2023 up 5697.69 % up 481.45 % - -
Celldex Therapeutics inc 4Q 2023 up 156.11 % up 172.31 % - -
Heska Corporation 1Q 2023 down-3.73 % down -5.96 % - -
Immucell Corp 3Q 2023 up 9.82 % up 73.03 % - -
Idexx Laboratories Inc 4Q 2023 up 8.76 % down -1.51 % up 12.96 % down -8.34 %
Lucira Health Inc 3Q 2022 up 157.53 % up 31.53 % - -
Lantheus Holdings Inc 4Q 2023 up 34.56 % up 11.02 % - down -21.66 %
Myriad Genetics Inc 4Q 2023 up 10.57 % up 2.45 % - -
Mymd Pharmaceuticals Inc 3Q 2023 - - - -
Navidea Biopharmaceuticals Inc 3Q 2023 - - - -
Neogen Corporation 3Q 2023 up 72.85 % down -5.2 % down -71.15 % down -73.03 %
Intellia Therapeutics Inc 3Q 2023 down-9.6 % down -11.78 % - -
Nymox Pharmaceutical Corporation 4Q 2022 - - - -
Ortho Clinical Diagnostics Holdings Plc 1Q 2022 down-1.32 % - - down -66.67 %
Oncocyte Corporation 3Q 2023 up 946.34 % down -7.34 % - -
Quidelortho Corp 3Q 2023 down-5.08 % up 11.86 % - -
Quotient Limited 1Q 2022 up 21.55 % up 12.36 % - -
Alpha Teknova Inc 3Q 2023 down-30.12 % down -32.48 % - -
Trinity Biotech Plc 4Q 2022 down-19.56 % down -19.56 % - -
Meridian Bioscience Inc 1Q 2022 up 30.45 % up 25.91 % up 9.31 % up 87.43 %
Volitionrx Limited 3Q 2023 up 405.02 % down -23.62 % - -
Revenue
In Vitro & In Vivo Diagnostic Substances Industry

recorded in the 4. Quarter 2023 above average Revenue deterioration of -98.79 % year on year, Total Ranking #11 and ranking within sector #1.

Sequentially Revenues for In Vitro & In Vivo Diagnostic Substances Industry fell by -91.88 %.

More on In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth




Income
In Vitro & In Vivo Diagnostic Substances Industry
in the 4. Quarter 2023 Net loss contracted year on year.

Sequentially, In Vitro & In Vivo Diagnostic Substances Industry Net loss narrowed from previous quarter.

More on In Vitro & In Vivo Diagnostic Substances Industry Income Growth










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com